A carregar...

A phase I trial using the proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for CNS malignancies

PURPOSE: To evaluate the toxicity and response rate of bortezomib with concurrent radiotherapy and temozolomide in the treatment of patients with CNS malignancies. PATIENTS AND METHODS: This open-label, dose-escalation, phase 1 clinical study evaluated the safety of 3 dose levels of intravenously ad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kubicek, Gregory J., Werner-Wasik, Maria, Machtay, Mitchell, Mallon, Gayle, Myers, Thomas, Ramirez, Michael, Andrews, David, Curran, Walter J., Dicker, Adam P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2697394/
https://ncbi.nlm.nih.gov/pubmed/19084346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2008.08.050
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!